

Table 1. Baseline characteristics according to clinical and virological outcome for 1 061 patients treated with at least HCQ + AZ ≥ 3 days at IHU Méditerranée infection Marseille, France with Day 0 between March 3 and March 31, 2020.

	Poor virological outcome	Good outcome	Poor clinical outcome	All
	n (%)	n (%)	n (%)	n (%)
Group size ^a	47 (4.4%)	973 (91.7%)	46 (4.3%)	1061 (100%)
Age (years)				
Mean(SD)	47.9 (17.5)*	42.4(14.7)	69.2(14.0)***	43.6(15.6)
Male	19 (40.4%)	450 (46.3%)	23 (50%)	492 (46.4)
Chronic condition(s) and treatment(s)				
Chronic conditions				
Cancer	0 (0%)	21 (2.2%)	7 (15.2%)***	28 (2.6%)
Diabetes	3 (6.4%)	66 (6.8%)	9 (19.6%)***	78 (7.4%)
Coronaryartery disease	2 (4.3%)	36 (3.7%)	9 (19.6%)***	46 (4.3%)
Hypertension	8 (17%)	120 (12.3%)	23 (50.0%)***	149 (14%)
Chronicrespiratorydiseases	8 (17%)	96 (9.9%)	8 (17.4%)	111 (10.5%)
Obesity	1 (2.1%)	57 (5.9%)	4 (8.7%)	62 (5.8%)
Comedication(s)				
Biguanides(metformin)	1 (2.1%)	15 (1.5%)	4 (8.7%)**	20 (1.9%)
Selective beta blocking agents	6 (12.8)**	22 (2.3%)	9 (19.6%)***	34 (3.2%)
Dihydropyridinederivatives	3 (6.4)	23 (2.4%)	8 (17.4%)***	34 (3.2%)
Angiotensin II receptor blockers	6 (12.8)**	22 (2.3%)	14 (30.4%)***	40 (3.8%)
HMG CoA reductaseinhibitors	4 (8.5)	28 (2.9%)	7 (15.2%)***	38 (3.6%)
Time between onset of symptoms and treatment start (days)^b				
Mean(SD)	4.3 (2.5)***	6.5(4.4)	5.9(4.0)	6.4(4.3)
Clinical classification(NEWS score)				
Mean(SD)	0.8(1.9)*	0.4(1.4)	5.4(3.5)***	0.6(1.8)
Median [Min-Max]	0.0 [0.0-8.0]*	0.0 [0.0-12.0]	5.5 [0.0-12.0]***	0.0 [0.0-12.0]
Pulmonary CT-scanner within 72 hours of admission^c				
Normal	11/37 (29.7%)	231/642 (36%)	4/39 (10.3%)	245/714 (34.3)*
Limited	23/37 (62.2%)	277/642 (43.2%)	10/39 (25.6%)	307/714 (43)*
Medium	3/37 (8.1%)	123/642 (19.2%)	20/39 (51.3%)	146/714 (20.5)*
Severe	0/37 (0%)	11/642 (1.7%)	5/39 (12.8)***	16/714 (2.2)*
Viral load at inclusion (Ct - nasal)^d				
Mean(SD)	22.5(4.5)***	26.3(4.7)	25.2(4.8)	26.1(4.8)
Median [Min-Max]	21.9 [14.8-32.8]***	26.7 [12.8-34.0]	25.4 [16.1-32.8]	26.4 [12.8-34.0]
Hydroxychloroquinelevels at day 2 (µg/mL)^e				
Mean(SD)	0.25 (0.17)	0.26 (0.16)	0.20(0.17)**	0.25(0.16)
Number ≤ 0.1 µg/mL	4/24 (16.7%)	15/206 (7.3%)	12/37 (32.4)***	30/263 (11.1%)

SD: standard deviation. ^a5 patients had both poor viral and clinical outcomes. ^bData available for 784 patients, ^cfor 714 patients, ^dfor 862 patients, and ^efor 263 patients. The denominator was mentioned when the result was not available for all patients. *: p<0.05; **p<0.01; ***p<0.001 (Fisher's exact test, Student t-test, Wilcoxon-Mann-Whitney where appropriate; reference group is good outcome).